{"id":811163,"date":"2025-02-10T16:19:13","date_gmt":"2025-02-10T21:19:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"modified":"2025-02-10T16:19:13","modified_gmt":"2025-02-10T21:19:13","slug":"diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","title":{"rendered":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>DiaMedica Therapeutics to Present at the Oppenheimer 35<sup>th<\/sup> Annual Healthcare Life Sciences Conference<\/b><\/p>\n<p>MINNEAPOLIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nDiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company\u2019s management will present at the Oppenheimer 35<sup>th<\/sup> Annual Healthcare Life Sciences Conference on February 12<sup>th<\/sup>, 2025 at 11:20am Eastern Time.<\/p>\n<p>\nInvestors and attendees that would like to schedule a meeting with DiaMedica\u2019s management can contact their Oppenheimer representative to arrange a meeting.<\/p>\n<p><b><i>About DiaMedica Therapeutics Inc.<\/i><\/b><\/p>\n<p>\nDiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica\u2019s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.diamedica.com&amp;esheet=54203451&amp;newsitemid=20250210075559&amp;lan=en-US&amp;anchor=www.diamedica.com&amp;index=1&amp;md5=25899fb74b3475e9ede973bf157cf8da\">www.diamedica.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250210075559\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250210075559\/en\/<\/a><\/span><\/p>\n<p>\nScott Kellen<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/>Phone: (763) 496-5118<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:skellen@diamedica.com\">skellen@diamedica.com<\/a><\/p>\n<p><b>For Investor Inquiries:<br \/>\n<\/b><br \/>Mike Moyer<br \/>\n<br \/>Managing Director, LifeSci Advisors, LLC<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mmoyer@lifesciadvisors.com\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Minnesota United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health FDA Other Health Clinical Trials Pharmaceutical Cardiology Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250210075559\/en\/2377886\/3\/DiaMedica-Logo_-_email_signature.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company\u2019s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica\u2019s management can contact their Oppenheimer representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica\u2019s lead candidate DM199 is the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-811163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company\u2019s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica\u2019s management can contact their Oppenheimer representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica\u2019s lead candidate DM199 is the &hellip; Continue reading &quot;DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-10T21:19:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference\",\"datePublished\":\"2025-02-10T21:19:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"wordCount\":232,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"name\":\"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-02-10T21:19:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","og_description":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211; DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company\u2019s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica\u2019s management can contact their Oppenheimer representative to arrange a meeting. About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica\u2019s lead candidate DM199 is the &hellip; Continue reading \"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-10T21:19:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference","datePublished":"2025-02-10T21:19:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"wordCount":232,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","name":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-02-10T21:19:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250210075559r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/diamedica-therapeutics-to-present-at-the-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=811163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/811163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=811163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=811163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=811163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}